Alpheus Medical
Health Care · Oncology Therapeutics
$81.8Mtotal raised · 7 rounds on record
$60.5Mlatest round · Series B · May 2025 · 18 mo ago
1backers · OrbiMed
50+team · employees, estimated range
Overview
Alpheus is advancing a new therapeutic approach designed to improve outcomes while reducing treatment burden for patients and families.
Funding and backers
Total raised
$81.8M
7 rounds on record
Latest round
$60.5M
Series B · May 2025 · 18 mo ago
Team
51-200
employees, estimated range
Backers
1
OrbiMed
The money's age
Due for its next round
18 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 30
Board appointment John Johnson, Director · SEC Form D
May 2, 2025
Raised a round Series B $60.5M · SEC Form D
Oct 25, 2022
Raised a round Series A $14M · SEC Form D
Dec 16, 2020
Raised a round Venture round $6M · SEC Form D
2020
Founded
Oct 4, 2019
Took on debt financing $519k · SEC Form D
Apr 25, 2018
Raised a round Venture round $1.3M · SEC Form D
Jan 21, 2018
Took on debt financing $150k · SEC Form D
May 24, 2017
Took on debt financing $225k · SEC Form D
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | May 2025 | $60.5M | — | SEC Form D |
| Series A | Oct 2022 | $14M | — | SEC Form D |
| Venture round | Dec 2020 | $6M | — | SEC Form D |
| Debt Financing | Oct 2019 | $519k | — | SEC Form D |
| Venture round | Apr 2018 | $1.3M | — | SEC Form D |
| Debt Financing | Jan 2018 | $150k | — | SEC Form D |
| Debt Financing | May 2017 | $225k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Alpheus Medical, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Vijay AgarwalExecutive Officer, DirectorSEC Form D
Terrance KurtenbachExecutive OfficerSEC Form D
Imran EbaExecutive OfficerSEC Form D
Jeremy LingExecutive OfficerSEC Form D
Steve WeinerExecutive OfficerSEC Form D
Patrick GoraExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Innovating life-changing medicines for cancer patients. At Kumquat, we're on a mission to transform cancer treatment by delivering durable…
Logic gated immunotherapies for cancer and autoimmune disease. Synolo Therapeutics is advancing a new class of therapeutics for cancer.
IDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells…
RS & RS Scientific leads in cutting-edge cancer therapy research, developing innovative therapies for challenging cancer treatments. Their…
Pioneering the first oral drug for FSHD and advancing cancer treatment solutions.
CAR T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers.
Financials
Total raised
$82.7M
Latest round
Series B
Funding rounds
7
People
Vijay Agarwal
Executive Officer, Director
Terrance Kurtenbach
Executive Officer
Imran Eba
Executive Officer
Jeremy Ling
Executive Officer
Steve Weiner
Executive Officer
Patrick Gora
Executive Officer
William Davis
Executive Officer
Peter Thompson
Director
Klaus Veitinger
Director
Aaron Sandoski
Director
Conrad Wang
Director
Juan-Pablo Mas
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Patients & Resources
Learn more about the Alpheus Brain Cancer Study and find additional information and resources for patients.
Read more
Report
Program Overview
Learn more about Alpheus Medical's platform, how the therapy works, and the challenges of Glioblastoma (GBM).
Read more
Report
Brain Tumor Investment Fund Highlights Alpheus in Portfolio Spotlight
Portfolio Spotlight: Alpheus Medical The post Brain Tumor Investment Fund Highlights Alpheus in Portfolio Spotlight first appeared on Alpheus Medical.
Read more
Report
Report
Alpheus Medical Initiates Phase 2b Trial of Investigational Therapy for Newly Diagnosed Glioblastoma
#top .av-special-heading.av-mgscrw80-cf0d1a8f25dd09ad4c34365cf304b866{ padding-bottom:10px; } body .av-special-heading.av-mgscrw80-cf0d1a8f25dd09ad4c34365cf304b866 .av-special-heading-tag .heading-char{ font-size:25px; } .av-special-heading.av-mgscrw80-cf
Read more
Report
Alpheus Medical Initiates Phase 2b Trial of Investigational Therapy for Newly Diagnosed Glioblastoma
Read more
Report
Report
Report
Report
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Chanhassen
United States
HQ
Corporate
50-200 est. staff
1266 Park Road, Chanhassen, MN 55317